Trial reportOpen forum infectious diseases2026
Contemporary Single and Multi-Tablet HIV Treatment Regimens Are Associated With Similar Levels of Viral Suppression.
Trial report in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Single-tablet regimens (STRs) are widely used to treat HIV but are often substantially more expensive than multi-tablet regimens (MTRs). Few data exist comparing the effectiveness of STRs compared to contemporary once-daily MTRs. Methods: We merged data on persons with HIV (PWH) insured through WA State Medicaid in 2023 with statewide, public health HIV RNA surveillance data and used Poisson regression to estimate the relative risk (RR) of viral suppression (HIV RNA <200 copies/mL) associated with different antiretroviral therapy (ART) regimens. Models adjusted for sex, age, race, ethnicity, time since HIV diagnosis, housing status, healthcare system providing care, region, and receipt of Ryan White services. Results: A total of 2599 (90.4%) of 2874 PWH were virally suppressed. In multivariate analysis, lower levels of viral suppression were significantly associated with female sex at birth, younger age, being unstably housed, and use of darunavir-containing MTRs, but not other ART regimens. Viral suppression was lower among persons treated with 2025 US guideline recommended 1st-line MTRs (dolutegravir [DTG] + emtricitabine [FTC]/tenofovir alafenamide [TAF], DTG + FTC/tenofovir disoproxil fumarate [TDF], DTG + lamivudine [3TC]) than bictegravir (BIC)/FTC/TAF, however, this difference was not significant (88.9% vs 91.6%, RR Conclusions: Differences in viral suppression between contemporary STRs and 1st-line MTRs, if any, are likely small. Factors other than drug efficacy-including cost-should inform decisions to use STRs versus 1st-line MTRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.